Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Shares Issued (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Shares Issued for 7 consecutive years, with $257000.0 as the latest value for Q3 2025.

  • Quarterly Shares Issued changed N/A to $257000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $895000.0 through Dec 2025, down 41.69% year-over-year, with the annual reading at $895000.0 for FY2025, 41.69% down from the prior year.
  • Shares Issued hit $257000.0 in Q3 2025 for Allogene Therapeutics, up from -$9.4 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $10.0 million in Q1 2025 to a low of -$9.4 million in Q2 2025.
  • Historically, Shares Issued has averaged $434529.4 across 5 years, with a median of $326000.0 in 2023.
  • Biggest five-year swings in Shares Issued: skyrocketed 1239.93% in 2021 and later tumbled 1251.78% in 2025.
  • Year by year, Shares Issued stood at -$3.6 million in 2021, then soared by 155.79% to $2.0 million in 2022, then tumbled by 72.05% to $564000.0 in 2023, then rose by 28.01% to $722000.0 in 2024, then plummeted by 64.4% to $257000.0 in 2025.
  • Business Quant data shows Shares Issued for ALLO at $257000.0 in Q3 2025, -$9.4 million in Q2 2025, and $10.0 million in Q1 2025.